Other ROS- and caspases-dependent cell death modalities have been shown by the combination of bortezomib with PCI-24781 (an HDAC inhibitor) synergized against a Hodgkin and a non-Hodkin lymphoma cell line [38]. Here, HDAC9 is linked to lymphoma.